JPRN-jRCT1080222680已完成3 期
A phase III, randomized, controlled study of mFOLFOX6 + bevacizumab combination therapy versus mFOLFOX6 + panitumumab combination therapy in chemotherapy-naive patients with KRAS/NRAS wild-type, incurable/unresectable, advanced/recurrent colorectal cancer
Kohei Shitara0 个研究点目标入组 823 人开始时间: 2014年12月5日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 823
研究概览
简要总结
For the efficacy, mFOLFOX6 + panitumumab demonstrated a statistically significant improvement in OS, the primary endpoint, as compared to mFOLFOX6 + bevacizumab in patients with RAS wild-type, left-sided metastatic colorectal cancer for both primary tumors occupying left-sided and overall. The safety profile of panitumumab was similar to what has already been reported without newly reported safety concerns.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 80age old（—）
- 性别
- All
入选标准
- •(1)Investigator* and subinvestigator judge a candidate is understand clinical trial and comply this protocol.
- •*Those who participates in conducting a study and oversight the study duties at a site.
- •(2)Patients who have given written consent to take part in the study after detailed explanation of the study prior to enrollment
- •(3)Aged >=20 to <80 years at the time of informed consent
- •(4)Patients with unresectable adenocarcinoma originating in the large intestine (excluding carcinoma of the appendix and anal canal cancer)
- •(5)Patients with lesion(s) that can be evaluated.
- •*It is not essential to be evaluated the tumor according to the RECIST ver. 1.1.
- •(6)Patients who have not received chemotherapy for colorectal cancer. Patients who experience relapse more than 24 weeks (168 days) after the final dose of perioperative adjuvant chemotherapy* with fluoropyrimidine agents may be enrolled.
- •*: Patients who have received perioperative adjuvant chemotherapy including oxaliplatin are excluded
- •(7)Patients classified as KRAS/NRAS wild-type** by KRAS/NRAS testing*.
- •*: KRAS/NRAS test will be performed using the in vitro diagnostic listed in the National Health Insurance.
- •**: Patients with no mutation in any of the codons shown below are considered wild type. It is not considered wild type if either of the codons are not evaluable or not tested.
- •KRAS: EXON2 (codon 12, 13), EXON3 (codon 59, 61),EXON4 (codon 117, 146)
- •NRAS: EXON2 (codon 12, 13), EXON3 (codon 59, 61),EXON4 (codon 117, 146)
- •(8)Patients who satisfy the following criteria for the major organ function in tests performed within 14 days prior to enrollment
- •1)Neutrophil count >= 1.5*10^3/microL
- •2)Platelet count >= 1.0*10^4/microL
- •3)Hemoglobin >= 9.0 g/dL
- •4)Total bilirubin =< 2.0 mg/dL
- •5)AST =< 100 IU/L (=<200 IU/L if liver metastases are present)
- •6)ALT =< 100 IU/L (=<200 IU/L if liver metastases are present)
- •7)Serum creatinine =< 1.5 mg/dL
- •8)PT-INR < 1.5 (< 3.0 for patients treated with oral warfarin)
- •9)Satisfies at least one of these conditions
- •( i ) Urine protein (dip stick method) =< 1+
- •(ii ) UPC (urine protein creatinine) ratio =< 1.0
- •(iii) Urinary protein =<1000mg/ 24hours
- •(9)ECOG performance status (PS) of 0 or 1
- •(10)Life expectancy of >= 3 months (90 days) after enrollment
排除标准
- •(1)Radiotherapy received within 4 weeks (28 days) prior to enrollment. Treatments aimed at relieving pain for bone metastases are excluded.
- •(2)Known brain metastasis or strongly suspected of brain metastasis
- •(3)Synchronous cancers or metachronous cancers with a disease-free period of =< 5 years (excluding colorectal cancer) excluding mucosal cancers cured or be possibly cured by regional resection (esophageal, stomach, and cervical cancer, non-melanoma skin cancer, bladder cancer, etc.).
- •(4)Body cavity fluid that requires treatment (pleural effusion, ascites, pericardial effusion, etc.)
- •(5)Patients who do not want to use contraception to prevent pregnancy, and women who are pregnant or breast-feeding, or test positive for pregnancy
- •(6)Nonhealing surgical wound (excluding implanted venous reservoirs)
- •(7)Active hemorrhage requiring blood transfusion
- •(8)Disease requiring systemic steroids for treatment (excluding topical steroids)
- •(9)The patient who has placed colonic stent
- •(10)Intestinal resection within 4 weeks prior to enrollment or colostomy within 2 weeks prior to enrollmentt
- •(11)History or obvious and extensive CT findings of interstitial pulmonary disease (interstitial pneumonia, pulmonary fibrosis, etc.)
- •(12)Patients with unstable angina, myocardial infarction, cerebral hemorrhage, arterial thromboembolism such as cerebral infarction, or have history of these desease less than 24 weeks (168 days) before registration (except for lacunar infarction asymptomatic)
- •(13)Serious drug hypersensitivity
- •(14)Local or systemic active infection requiring treatment, or fever indicating infection
- •(15)NYHA class II or higher heart failure or serious heart disease
- •(16)Intestinal paralysis, gastrointestinal obstruction, or uncontrollable diarrhoea (incapacitating symptoms despite adequate treatment)
- •(17)Poorly controlled hypertension
- •(18)Poorly controlled diabetes mellitus
- •(19)Active hepatitis B
- •(20)Known HIV infection
- •(21)Peripheral neuropathy of >= Grade 2 by CTCAE (Japanese edition JCOG version 4.03)
- •(22)Other patients judged by the investigator or subinvestigator to be ineligible for enrollment in the study (e.g. Patients who might agree to participate under compulsion).
研究者
相似试验
已完成
3 期
A phase III, randomized, controlled study of mFOLFOX6 + bevacizumab combination therapy versus mFOLFOX6 + panitumumab combination therapy in chemotherapy-naive patients with KRAS/NRAS wild-type, incurable/unresectable, advanced/recurrent colorectal cancercolorectal cancerJPRN-UMIN000016776ational Cancer Center Hospital East823
已完成
3 期
PARADIGM study (PAnitumumab and RAS, DIagnostically-useful Gene Mutation for mCRC)Colorectal cancerJPRN-jRCTs031180246Shitara Kohei823
已完成
3 期
Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRCColorectal CancerNCT02394795Takeda823
进行中（未招募）
3 期
Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal CancerColorectal CancerNCT03635021Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)419
Unknown
3 期
Study Investigating the Role of Oxaliplatin Duration in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Colon Cancer TherapyColon CancerNCT01092481Samsung Medical Center1,580